Angina pectoris - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Angina pectoris - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Angina pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Angina pectoris: Overview
Angina pectoris is the medical term for chest pain or discomfort due to coronary heart disease. It occurs when the heart muscle doesn't get as much blood as it needs. This usually happens because one or more of the heart's arteries is narrowed or blocked, also called ischemia. Chest pain is the symptom, but it affects people differently. People may also experience: Aching, Burning, Discomfort, Dizziness, Fatigue, Feeling of fullness in your chest, Feeling of heaviness or pressure, Upset stomach or vomiting, Shortness of breath, Squeezing, Sweating. There are different types of angina:
Stable angina: This is the most common. Physical activity or stress can trigger it. It usually lasts a few minutes, and it goes away on rest.
Unstable angina: This occurs at rest or not very active. The pain can be strong and long-lasting, and it may come back again and again.
Microvascular angina: Chest pain but no coronary artery blockage.
Prinzmetal's angina (variant angina): This type is rare. It might happen at night while sleeping or resting.
People with angina pectoris or sometimes referred to as stable angina have episodes of chest pain. The discomfort that are usually predictable and manageable. Normally this type of chest discomfort is relieved with rest, nitroglycerin or both. Nitroglycerin relaxes the coronary arteries and other blood vessels, reducing the amount of blood that returns to the heart and easing the heart's workload. By relaxing the coronary arteries, it increases the heart's blood supply.
Report Highlights
This segment of the Angina pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angina pectoris Emerging Drugs
It is currently in Phase II stage of development for Angina pectoris and is being developed by Imbria pharmaceticals.
Further product details are provided in the report..
Angina pectoris: Therapeutic Assessment
This segment of the report provides insights about the different Angina pectoris drugs segregated based on following parameters that define the scope of the report, such as:
Angina pectoris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angina pectoris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina pectoris drugs.
Angina pectoris Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Angina pectoris - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Angina pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Angina pectoris: Overview
Angina pectoris is the medical term for chest pain or discomfort due to coronary heart disease. It occurs when the heart muscle doesn't get as much blood as it needs. This usually happens because one or more of the heart's arteries is narrowed or blocked, also called ischemia. Chest pain is the symptom, but it affects people differently. People may also experience: Aching, Burning, Discomfort, Dizziness, Fatigue, Feeling of fullness in your chest, Feeling of heaviness or pressure, Upset stomach or vomiting, Shortness of breath, Squeezing, Sweating. There are different types of angina:
Stable angina: This is the most common. Physical activity or stress can trigger it. It usually lasts a few minutes, and it goes away on rest.
Unstable angina: This occurs at rest or not very active. The pain can be strong and long-lasting, and it may come back again and again.
Microvascular angina: Chest pain but no coronary artery blockage.
Prinzmetal's angina (variant angina): This type is rare. It might happen at night while sleeping or resting.
People with angina pectoris or sometimes referred to as stable angina have episodes of chest pain. The discomfort that are usually predictable and manageable. Normally this type of chest discomfort is relieved with rest, nitroglycerin or both. Nitroglycerin relaxes the coronary arteries and other blood vessels, reducing the amount of blood that returns to the heart and easing the heart's workload. By relaxing the coronary arteries, it increases the heart's blood supply.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Angina pectoris R&D. The therapies under development are focused on novel approaches for Angina pectoris.
This segment of the Angina pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angina pectoris Emerging Drugs
- CLBS14: Caladrius Biosciences
- IMB-101: Imbria pharmaceticals
It is currently in Phase II stage of development for Angina pectoris and is being developed by Imbria pharmaceticals.
Further product details are provided in the report..
Angina pectoris: Therapeutic Assessment
This segment of the report provides insights about the different Angina pectoris drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Angina pectoris
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Angina pectoris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angina pectoris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina pectoris drugs.
Angina pectoris Report Insights
- Angina pectoris Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Angina pectoris drugs?
- How many Angina pectoris drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Angina pectoris?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angina pectoris therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angina pectoris and their status?
- What are the key designations that have been granted to the emerging drugs?
- Imbria pharmaceticals
- Arbor Pharmaceuticals
- Caladrius Biosciences
- XyloCor Therapeutics
- IMB101
- AR36
- CLBS 14
- XC-001
Introduction
Executive Summary
Angina pectoris: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angina pectoris– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Angina pectoris companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Angina pectoris Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AR36: Arbor Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria pharmaceticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
XC-001: XyloCor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Angina pectoris Key Companies
Angina pectoris Key Products
Angina pectoris- Unmet Needs
Angina pectoris- Market Drivers and Barriers
Angina pectoris- Future Perspectives and Conclusion
Angina pectoris Analyst Views
Angina pectoris Key Companies
Appendix
Executive Summary
Angina pectoris: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angina pectoris– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Angina pectoris companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Angina pectoris Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AR36: Arbor Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101: Imbria pharmaceticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
XC-001: XyloCor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Angina pectoris Key Companies
Angina pectoris Key Products
Angina pectoris- Unmet Needs
Angina pectoris- Market Drivers and Barriers
Angina pectoris- Future Perspectives and Conclusion
Angina pectoris Analyst Views
Angina pectoris Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Angina pectoris
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Angina pectoris
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Angina pectoris
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Angina pectoris
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
